0.82
+6.18%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Coherus Oncology
From its filings with the US Securities and Exchange Commission
Coherus Oncology is based in Redwood City, California and is incorporated in Delaware. Its shares trade on Nasdaq under the ticker CHRS. The SEC classifies its business as biological products, (no diagnostic substances). In the fiscal year to 31 December 2025, it reported revenue of $42.2m and net income of $168.0m. At that date it held total assets of $258.3m and shareholders' equity of $61.0m.
We are a fully integrated commercial-stage innovative oncology company with an approved next-generation programmed death receptor-1 (“PD-1”) inhibitor, LOQTORZI® (toripalimab-tpzi), and a pipeline that includes two mid-stage clinical candidates targeting liver, head and neck, colorectal and other cancers. Our strategy is to grow sales of LOQTORZI in nasopharyngeal carcinoma (“NPC”) and advance the development of new indications for LOQTORZI in combination with both our pipeline candidates as well as our partners, driving sales multiples and synergies from proprietary combinations. On May 29, 2025, we changed our corporate name from “Coherus BioSciences, Inc.” to “Coherus Oncology, Inc.” to better align with our exclusive focus on proprietary innovative immuno-oncology medicines following the completion of the recent divestitures of our biosimilar businesses.
On October 27, 2023, we announced that LOQTORZI was approved by the U.S. Food and Drug Administration (“FDA”) in combination with cisplatin and gemcitabine for the first-line treatment of adults with metastatic or recurrent locally advanced nasopharyngeal carcinoma, and as monotherapy for the treatment of adults with recurrent unresectable, or metastatic NPC with disease progression on or after platinum-containing chemotherapy. LOQTORZI is an anti-PD-1 antibody that we developed in collaboration with Junshi Biosciences Co., Ltd. (“Junshi Biosciences”) that is currently the only immune checkpoint inhibitor approved by the FDA for the treatment of these indications that is commercially available in the United States.
Quoted from its 10-K, filed 9 Mar 2026. Read the filing on SEC.gov ↗
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 6 Nov 2014
- Employees
- 147
- Website
- coherus.com ↗
- Head office
- C/O DENNIS M. LANFEAR, REDWOOD CITY, CA, 94065
- Incorporated in
- DE
- Classification
- Biological Products, (No Diagnostic Substances)
- Filer status
- Accelerated filer<br>Smaller reporting company
Leadership
Pay as last reported
- Mr. Dennis LanfearChairman of the Board, President, Chief Executive Officer, since 2010$4.8m
- Mr. Bryan McmichaelChief Financial Officer$1.0m
- Dr. Theresa LavalleeChief Development Officer
- Mr. Mats WahlstromLead Independent Director$252,032
- Ms. Georgia ErbezIndependent Director$287,390
- Ms. Rita KarachunIndependent Director$243,122
- Dr. Lee NewcomerIndependent Director$190,157
- Mr. Charles NewtonIndependent Director$208,907
- Dr. Jill O'Donnell-TormeyIndependent Director$185,782
- Dr. Michael RyanIndependent Director$199,532
- Mr. Ali SatvatIndependent Director$79,375
- Ms. Jami TaylorHead of Investor Relations, since 2025
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 25
- Environment
- 12
- Social
- 41
- Governance
- 23
- Women in the workforce
- 51%
- Carbon reduction policy
- No
- Human rights policy
- No
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Coherus BioSciences Inc possesses several key strengths that contribute to its success in the biopharmaceutical industry. These strengths include:
Weaknesses
- Despite its strengths, Coherus BioSciences Inc also faces certain weaknesses that pose challenges to its growth and competitiveness. These weaknesses include:
Opportunities
- Coherus BioSciences Inc can capitalize on several opportunities within the biopharmaceutical industry, including:
Threats
- Coherus BioSciences Inc faces certain threats that may impact its business operations and profitability. These threats include:
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.